论文部分内容阅读
目的观察可手术乳腺癌患者应用新辅助化疗治疗的临床疗效。方法对本院肿瘤科2010年1月至2012年12月62例新辅助化疗乳腺癌患者的临床资料进行回顾性分析,应用TAC方案化疗后给予手术治疗,分析临床治疗后疗效。结果 62例乳腺癌患者中23例达到CR,其中病理完全缓解9例;SD 8例,PR 31例,临床总有效率84.4%,17例患者经新辅助化疗后由不能保乳变为可给予保乳治疗。结论采用TAC联合化疗方案对可手术乳腺癌患者进行新辅助化疗,可以缩小肿瘤、降低临床分期,提高保乳手术机会。
Objective To observe the clinical effect of neoadjuvant chemotherapy in patients with operable breast cancer. Methods The clinical data of 62 patients with neoadjuvant chemotherapy for breast cancer from January 2010 to December 2012 in our hospital were analyzed retrospectively. TAC regimen was given to patients after operation, and the effect after clinical treatment was analyzed. Results Twenty-three of 62 breast cancer patients achieved CR, of which 9 were completely relieved of pathology; 8 were SD and 31 were PR, with a total clinical effective rate of 84.4%. Seventeen patients were treated with neoadjuvant chemotherapy, Breast-conserving treatment. Conclusion TAC combined with chemotherapy for patients with operable breast cancer neoadjuvant chemotherapy, can reduce the tumor, reduce the clinical stage, improve the chance of breast-conserving surgery.